FY2024 · ended Dec 31, 2024 · Revenue $582,000, +755.9% YoY · Filed Mar 13, 2026
Ernexa Therapeutics Inc. (ERNA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$7.1 million. As of Jun 30, 2026 it held $5.0 million in cash and investments and $349,000 in total debt.
Revenue
$582,000
+755.9% vs prior year
Net income
$-14.08M
+68.4% vs prior year
Operating cash flow (TTM)
$-8.84M
+38.8% vs year-ago TTM
Free cash flow (TTM)
$-9.14M
EPS
$-2.24
+95.4% vs prior year
Dividend per share
None
Shares outstanding
29.15M
-44.2% vs prior year
Net cash
$4.68M
as of Jun 30, 2026
Operating margin
-2693.1%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ERNA (Nasdaq), ERNAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 748592
- Former names
- Eterna Therapeutics Inc. (until Apr 4, 2025); Brooklyn ImmunoTherapeutics, Inc. (until Oct 14, 2022); NTN BUZZTIME INC (until Mar 23, 2021); NTN COMMUNICATIONS INC (until Dec 20, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $582,000 | $68,000 | — | — |
| Operating income | -$9.3M | -$15.7M | -$21.1M | -$33.2M | -$113.7M |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M | -$122.5M |
| Diluted EPS | -$2.24 | -$48.96 | -$4.08 | -$8.06 | -$56.61 |
| Operating cash flow | -$7.0M | -$15.8M | -$20.4M | -$21.0M | -$23.5M |
| Free cash flow | -$7.1M | -$16.2M | -$20.4M | -$21.3M | -$23.6M |
| Total assets | $5.8M | $5.3M | $49.1M | $22.3M | $31.5M |
| Total liabilities | $3.4M | $3.6M | $46.9M | $10.2M | $6.0M |
| Stockholders' equity | $2.4M | $1.7M | $2.2M | $12.1M | $25.5M |
| Cash and investments | $1.9M | $1.7M | $7.6M | $11.4M | $17.0M |
| Total debt | $490,000 | $684,000 | $35.1M | $1.2M | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 2, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 2, 2026 | Jul 1, 2026 |
All 1000 Ernexa Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.